Adalimumab biosimilar - Zhejiang Hisun Pharmaceuticals
Alternative Names: Anjianning; Dalimab; HS 016Latest Information Update: 12 Oct 2025
At a glance
- Originator Zhejiang Hisun Pharmaceutical
- Developer Searle Company Limited; Zhejiang Hisun Pharmaceutical
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Ankylosing spondylitis; Crohn's disease; Hidradenitis suppurativa; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis; Uveitis
Most Recent Events
- 02 Oct 2025 Adalimumab biosimilar (Dalimab™) has a boxed warning for the increased risk for developing serious infections and lymphoma along with other malignancies in children and adolescent patients treated with TNF blockers including Adalimumab
- 02 Oct 2025 Launched for Ankylosing spondylitis in Pakistan (SC) (Searle Website, October 2025)
- 02 Oct 2025 Launched for Crohn's disease (In adolescents, In children) in Pakistan (SC) (Searle Website, October 2025)